EU poised to approve first single-shot COVID-19 and flu vaccine for 50+
The European Medicines Agency recommended EU-wide marketing authorisation for mCombriax, the first combined mRNA vaccine protecting people aged 50 and older against both COVID-19 and seasonal influenza in a single shot. In trials, antibodies against both viruses were non-inferior to existing vaccines, and the vaccine showed common short-term side effects (injection-site pain, fatigue, muscle/joint pain, fever, etc.). The European Commission will decide on authorization, after which price and reimbursement are set by individual member states.
